Mr. Gary Thompson reports

CALLITAS HEALTH ANNOUNCES PATENT APPLICATION FOR CANNAMINT STRIPS

Callitas Health Inc. has received confirmation from the U.S. Patent and Trademark Office (USPTO) of the pending patenting status for recently submitted technology for the bioavailability of cannabinoids branded as CannaMint Strips by Callitas.

The latest Callitas technology, formally titled as "Orally Dissolving Mucoadhesive Films Utilizing Menthol And L-Arginine To Enhance The Bioavailability of Cannabinoids," provides a unique opportunity for cannabis/cannabidiol distributers looking to in-license the company's technology to differentiate themselves in an increasingly competitive marketplace.

"Our Callitas patented and patent-pending combination of menthol and l-arginine has provided a unique foundation to advance the delivery of cannabis technology," said James Thompson, Callitas's chief operating officer and co-inventor of this patent technology. "The direct distribution of cannabinoids does not fit into our Callitas business model, but licensing this technology to manufacturers and distributors in North America advances our goal of improving health and wellness," added Mr. Thompson.

Callitas Therapeutics Inc. technology

Callitas Therapeutics is the global owner of patented and patent-pending technology related to the use of compositions that include menthol and l-arginine: U.S. patent Nos. 6,989,163, 6,702,733 and 6,322,493 and corresponding international patents. Recently the company's work and research have developed an orally dissolving mucoadhesive copolymer matrix of menthol, l-arginine, and one or more cannabinoids, such as tetrahydrocannabinol or tetrahydrocannabinol, for the enhanced pharmacokinetic bioavailability of the cannabinoids. The orally dissolving menthol and l-arginine function to provide enhanced cannabinoid bioavailability while avoiding first-pass liver breakdown of inhaled or ingested cannabinoids.

The orally dissolving thin strips have menthol and l-arginine formulated into their matrix and will include a microporous, porous or even honeycomb design to absorb cannabinoids; CBD cannabinoid oil (non-psychoactive) applied for medicinal use; and THC cannabinoid oil (psychoactive) applied for medical or recreational use (where applicable). The legal intrastate recreational use of THC cannabinoid oil with increased bioavailability could compete with illegal oral and injectable opioids without the risk of respiratory depression and drug overdose deaths.

About Callitas Health Inc.

Formed in early 2015, Callitas Health is a clinical-stage company developing innovative technologies for obesity, weight management, and female health and wellness.

We seek Safe Harbor.